Chemed (CHE) Earnings Date & Reports

Key Takeaways

• Chemed reported third-quarter 2026 revenue of $690.9 million, up 10.6% from $624.9 million a year earlier.
• Adjusted (non-GAAP) earnings per share (EPS) came in at $6.75, beating the consensus estimate of $6.44 by about 4.9%.
• GAAP (Generally Accepted Accounting Principles) diluted EPS rose 22.2% to $5.45, from $4.46 in the prior-year quarter.
• The VITAS hospice segment drove results with 12.2% revenue growth, while the Roto-Rooter segment grew revenue 7.5%.
• Management said full-year 2026 adjusted EPS is expected to be at or slightly above the high end of prior guidance.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper analysis.
• Looking for trade ideas and market signals? Explore Trending AI Robots to see AI-driven strategies in action.

Earnings Context and Why It Matters

Chemed Corporation operates two distinct businesses: VITAS, one of the largest hospice care providers in the United States, and Roto-Rooter, a leading plumbing and drain-cleaning services franchise. This dual structure makes quarterly results a useful barometer for both healthcare services demand and consumer discretionary repair spending. Heading into the report, investors were watching whether VITAS could sustain its strong patient census growth and whether Roto-Rooter could keep expanding despite a softer consumer environment. The third quarter also carried strategic significance, as Chemed re-acquired California franchise territories for Roto-Rooter during the period, a move that reshapes the segment's footprint and long-term growth profile.

Reported Results

For the quarter ended September 30, 2026, Chemed reported service revenues and sales of $690.9 million, a 10.6% increase from $624.9 million in the same period last year. This modestly exceeded analyst consensus estimates of roughly $684.5 million.

On a GAAP basis, net income was $71.6 million, with diluted EPS of $5.45, up 22.2% from $4.46 a year ago. Adjusted (non-GAAP) EPS was $6.75, beating the consensus estimate of $6.44 by approximately 4.9%. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $133.8 million, slightly above the $130.9 million analysts had projected, with an adjusted EBITDA margin of 19.4%.

Segment-level results were strong across the board. VITAS revenue rose 12.2% to $457.4 million, supported by a 9.4% increase in average daily census to 24,428 patients and a 7.2% rise in admissions to 18,995. Roto-Rooter revenue grew 7.5% to $233.5 million. Operating margin improved to 14%, up from 12% in the prior-year quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Chemed, it offers a structured way to surface comparable opportunities and monitor evolving market conditions.

Market Reaction and Investor Sentiment

Following the release, Chemed shares were broadly steady, trading near the $505 to $509 range in after-hours and pre-market activity. The relatively muted price response reflects that investors had already priced in continued strength from VITAS, though the earnings and revenue beats, combined with management's upbeat full-year commentary, were viewed as confirming the company's growth trajectory. Over the prior three months, the stock had slipped modestly, while the 12-month performance remained positive. The key sentiment driver was the durability of VITAS's patient census growth and the raised full-year adjusted EPS outlook, which reinforced confidence in Chemed's core hospice franchise.

Forward Outlook and Key Factors to Monitor

Chemed indicated that full-year 2026 adjusted EPS is expected to be at or slightly above the high end of the guidance range it issued in July. This suggests management sees continued operating momentum through the fourth quarter, supported by strong demand in hospice care and steady plumbing services activity.

Investors should watch VITAS's average daily census and admission trends, since these metrics are the primary drivers of hospice revenue growth and are sensitive to labor availability, regulatory changes, and Medicare (the federal health insurance program) reimbursement policy. Capacity expansion and clinician recruitment will remain central to sustaining double-digit segment growth.

On the Roto-Rooter side, the re-acquisition of California franchise territories for approximately $62.5 million is a notable strategic shift that adds direct operating responsibility and could influence near-term margins as the territories are integrated. Consumer spending on discretionary home repair remains a variable worth monitoring.

Finally, capital allocation will be in focus. Chemed repurchased 125,000 shares for $66.0 million during the quarter, and investors will likely track whether buybacks continue alongside the franchise acquisitions and any debt management initiatives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations